Clinical Trials Logo

Clinical Trial Summary

Study the efficacy of endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar to prevent neovascular glaucoma and secondary enucleation


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02874040
Study type Interventional
Source Institut Curie
Contact
Status Active, not recruiting
Phase N/A
Start date April 19, 2013
Completion date October 24, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Active, not recruiting NCT05542342 - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Phase 2
Completed NCT02849145 - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) N/A
Recruiting NCT01438658 - Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma N/A
Not yet recruiting NCT00811200 - Treatment Of Radiation Retinopathy Trial Phase 2/Phase 3
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Recruiting NCT05077280 - A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Completed NCT04551352 - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Phase 1
Not yet recruiting NCT06246149 - Adjuvant Tebentafusp in High Risk Ocular Melanoma Phase 3
Completed NCT01955941 - Vascular Response to Brachytherapy Using Functional OCT
Completed NCT00661622 - Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Phase 2
Recruiting NCT05502900 - Adjuvant Melatonin for Uveal Melanoma Phase 3
Active, not recruiting NCT03070392 - Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Phase 2
Recruiting NCT06284512 - Uveal Melanoma - Comparative Study
Recruiting NCT05524935 - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Phase 2
Active, not recruiting NCT02913417 - Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Phase 1/Phase 2
Not yet recruiting NCT06073548 - Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study